Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 4Glioma 2Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Pemetrexed 19Bevacizumab 10Radiotherapy 8Spinal Puncture 7osimertinib 6Methotrexate 6Magnetic Resonance Spectroscopy 6aflutinib 5Topotecan 5Specimen Handling 5Trastuzumab 4Temozolomide 4Radiotherapy, Intensity-Modulated 4Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2omburtamab I-131 2merphos 2aumolertinib 2WP 744 2Vitamin B 12 2Rituximab 2Radiation 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2Capecitabine 2Busulfan 2AZD3759 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Meningeal Carcinomatosis × azeliragon × Clear all
NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡